Executive Summary
A 300,927-patient real-world TAVR cohort shows clinically significant valve failure requiring repeat intervention occurs earlier after TAVR than after SAVR — and while redo-TAVR carries lower perioperative risk than surgical explant, propensity-matched survival favors explantation (HR 0.64, 95% CI 0.44-0.93), sharpening the durability question the ESC 2025 age-70 pivot to TAVI has left unresolved. Transfemoral TMVR data from the CHOICE-MI registry (n=124, nine devices) reported 91.1% technical success but a 44.1% composite death/HF hospitalization rate at one year — feasible, not yet convincing. The LuX-Valve Plus European TRINITY cohort achieved 91.2% 30-day clinical success in large-annulus TTVR (n=114), extending the transcatheter tricuspid envelope into anatomy previously written off. Together, these findings tighten the lifetime-management case and complicate the low-risk TAVR narrative.
- Contemporary TAVR 30-day MACE fell from 31.8% pre-2017 to 18.6% post-2022, but clinically significant valve failure arrives sooner than after SAVR (Epic Cosmos, n=300,927).
- Transfemoral TMVR eliminated MR in 74.4% and reduced it to ≤1+ in nearly all patients through 2 years across nine devices (CHOICE-MI, JACC: CV Interventions).
- LuX-Valve Plus TTVR in large annuli (55-70 mm) achieved 95.6% intraprocedural success with 6.1% new pacemaker rate (TRINITY, EuroIntervention).
- GDF-15 outperformed NT-proBNP for 1-year mortality after transcatheter tricuspid intervention (AUC 0.795 vs non-significant) (CJC Open, n=100).
- A sheath-to-artery diameter ratio ≥1.07 was the strongest independent predictor of vascular access complications (OR 6.71) in large-bore femoral access (CCI, n=530 matched).
What to watch: TCT 2026 late-breakers on TAVR durability at 8-10 years, where the Epic Cosmos signal on earlier reintervention will meet head-to-head with PARTNER 3 and Evolut Low Risk extended follow-up.
Aortic Valve (TAVR/TAVI)
[NOTABLE] The largest real-world TAVR dataset yet published complicates — not resolves — the durability debate. Using Epic Cosmos, Ma et al. tracked 300,927 index TAVR patients from 2010 to 2026, documenting a >10-fold volume increase since 2016 and 30-day mortality falling from 3.0% to 1.4%. Cumulative reintervention was 2.7% at 10 years — reassuringly low — but the landmark analysis found clinically significant valve failure requiring repeat intervention occurred earlier after TAVR than after SAVR. Among propensity-matched survivors, surgical explantation carried superior long-term survival versus redo-TAVR (HR 0.64, 95% CI 0.44-0.93; P=0.018), despite worse perioperative outcomes. ACC/AHA 2020 still favors SAVR under age 65 on durability grounds; ESC 2025 shifted TAVI-preferred to age ≥70, citing comparable structural valve deterioration rates at available follow-up — a position this dataset challenges without yet overturning. This is a retrospective EHR-derived analysis with the expected coding and selection biases; clinically significant valve failure is defined by reintervention rather than hemodynamic criteria, and there is no core-lab echo adjudication. The signal aligns with prior TVT Registry data showing 12-17% explant mortality. The Epic Cosmos data support the ESC pivot on procedural safety but leave the lifetime-management question — where does the third valve go? — unanswered.
Adjacent findings tighten the procedural picture. A Netherlands Heart Journal comparison of TAV-in-TAV vs TAV-in-SAV (n=56) found invasive mean gradients were similar for balloon- and self-expanding valves (6.0 vs 7.0 mmHg), but TTE overestimated BEV gradients by a median of 13 mmHg in TAV-in-SAV — a pressure-recovery artifact clinicians should not treat as prosthesis-patient mismatch. A retrospective cohort of 180 patients undergoing concomitant vs staged PCI+TAVR found no significant early outcome differences, though 5% stroke in the concomitant arm (vs 0%) is not nothing in a study this size. A CALLY index analysis (n=812) identified the C-reactive protein-albumin-lymphocyte ratio as an independent predictor of 30-day pacemaker requirement (Q4 HR 0.57) — a cheap inflammatory marker worth prospective validation. Transaxillary TAVR is being formalized as the preferred alternative access when transfemoral is prohibited.
Mitral Valve (MitraClip, PASCAL, TMVR)
Transfemoral TMVR gets its most complete registry snapshot to date, and the results are honest: feasible, not yet definitive. JACC: Cardiovascular Interventions published the CHOICE-MI transfemoral cohort — 124 patients, nine devices (AltaValve, CardiAQ, Cardiovalve, Cephea, Evoque, HighLife, Innovalve, Intrepid, Sapien M3), median age 79, 80% with AF, 67% with CAD. Technical success was 91.1% and procedural mortality 0.8%. MR was eliminated in 74.4% and reduced to ≤1+ in nearly all echo-evaluable patients through 2 years, with progressive reverse remodeling. The composite of all-cause mortality, cardiovascular mortality, and HF hospitalization hit 44.1% at 1 year and 52.4% at 2 years; cardiovascular mortality alone was 20.3% at 2 years. AF was an independent predictor of poor outcome — mirroring the M-TEER literature. Nine devices pooled across a decade in a rescue population, with no surgical or TEER comparator arm: the numerator is durability, the denominator is late referral. ACC/AHA 2020 and ESC 2025 both keep MV repair as Class I for primary MR with an expected durable result; ESC 2025 upgraded TEER to Class I for COAPT-like ventricular SMR. Transfemoral TMVR sits below both — a bailout for patients with neither surgical nor TEER anatomy. The registry justifies continued development, not guideline movement.
Tricuspid Valve (TriClip, TTVR)
The transcatheter tricuspid envelope expanded on two fronts. The European TRINITY cohort of the LuX-Valve Plus system (n=114, EuroIntervention) enrolled patients with tricuspid annuli 55-70 mm — anatomy excluded from most TTVR platforms. Mean age 77.8, mean STS 9.9%. Intraprocedural success was 95.6% with zero intraprocedural mortality or stroke; 30-day clinical success was 91.2%, driven by 93.7% achieving moderate-or-less residual TR. KCCQ improved from 57.3 to 71.0, and NYHA III-IV dropped from 57.1% to 20.9%. New pacemaker rate was 6.1% — well below the 12-13% reported after EVOQUE implantation. ESC 2025 gives transcatheter TV treatment Class IIa (LOE A) for high-risk symptomatic severe TR; ACC/AHA 2020 does not address the therapy. The TRINITY data extend LuX-Valve Plus into anatomy where no Class IIa recommendation currently applies, and the JACC Case Reports piece on delayed AV block after EVOQUE with leadless rescue underscores why the 6.1% pacemaker figure matters for long-term prosthesis management.
A CJC Open biomarker study (n=100) found GDF-15 (AUC 0.795) and suPAR (AUC 0.746) outperformed NT-proBNP — which did not significantly predict 1-year mortality — after transcatheter tricuspid intervention. Combining GDF-15 with right atrial pressure pushed AUC to 0.805. Single-center, small, and not yet externally validated; the signal is internally consistent with the too-late-referral problem ESC 2025 flags explicitly in its tricuspid section. Neither finding moves the guideline, but together they extend anatomic reach and refine which patients retain meaningful benefit. Lansky's EuroIntervention editorial on stroke prevention in TAVI beyond solid emboli — while aortic-focused — reinforces that the transcatheter field's next frontier is patient selection biomarkers, not device iteration alone.
Surgical vs. Transcatheter Comparisons
Two datasets speak directly to the surgical-transcatheter balance. The Epic Cosmos national cohort is the more consequential: after propensity matching among hospital survivors, surgical explantation of failed TAVR carried better long-term survival than redo-TAVR (HR 0.64). This does not indict TAVR, but it complicates ESC 2025's expansion of TAVI-preferred to age ≥70, because patients in their 70s with 15+ year life expectancies may be committing to a redo pathway with worse survival than the SAVR alternative would have offered at index. ACC/AHA 2020's more conservative age-based framework — SAVR under 65, shared decision 65-80 — is more defensible under these data than it was before this preprint. The CHOICE-MI TMVR cohort has no surgical comparator, but its 52% two-year composite event rate is a floor against which any future TMVR-vs-surgery trial will be judged. Surgical MV repair in appropriately selected primary MR still delivers 5-year survival north of 90% at experienced centers.
Preprint Highlights
The Ma et al. Epic Cosmos analysis (medRxiv preprint, not yet peer-reviewed) is the single most important data drop today. Retrospective EHR-based cohort of 300,927 TAVR patients — an order of magnitude larger than any published TVT Registry analysis. Strengths: real-world contemporary practice, competing-risk methodology, propensity matching. Weaknesses: EHR coding fidelity, no core-lab echo adjudication, and clinically significant valve failure defined by reintervention rather than hemodynamic criteria. The finding that TAVR reinterventions occur earlier than SAVR reinterventions — even at lower cumulative incidence — deserves peer-reviewed publication and independent replication before it drives guideline change, but it lands squarely in an active debate about lifetime management.
Device & Technology
Access matters more than the field admits. A nested case-control study in Catheterization and Cardiovascular Interventions (177 cases, 353 matched controls) established a sheath-to-artery diameter ratio ≥1.07 as the strongest independent predictor of vascular complications (OR 6.71, AUC 0.83, bootstrap-corrected AUC 0.91). Ultrasound-guided puncture (OR 0.15) and fluoroscopy-guided access (OR 0.14) were strongly protective. As TAVR sheath profiles keep shrinking, this ratio should be a mandatory pre-procedural CTA metric — and the protective effect of image guidance is an argument against continued reliance on landmark-based femoral puncture in 2026. The transaxillary TAVR technical narrative from JACC Case Reports formalizes what many high-volume centers already practice as the preferred non-femoral route.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $90.98, +0.19% on the day; 6-month return +15.28%; 52-week range $72.30-$96.29
- Market cap $52.4B; trailing P/E 54.15, forward P/E 26.95; beta 0.85
- Analyst target $100.96 (26 analysts, buy); range $84-$110
- Next earnings Oct 29, 2026 (EPS est $0.74, revenue est $1.68B)
EW has ridden a 15% six-month rally as the Sapien franchise and the Evoque tricuspid platform both continue delivering. TRINITY's LuX-Valve Plus data reaching 70 mm annuli is a competitive shot across the bow — Edwards remains the dominant TTVR player, but the anatomic ceiling on Evoque is now being tested by rivals. The Epic Cosmos TAVR reintervention data is neutral to negative for the sector but historically has not moved Edwards on daily timescales.
Medtronic (MDT)
- Close $92.09, +1.64% on the day; 6-month return -4.00%; 52-week range $73.31-$106.33
- Market cap $117.9B; trailing P/E 24.3, forward P/E 14.36; beta 0.57
- Analyst target $98.44 (25 analysts, buy); range $78-$121
- Next earnings Sep 1, 2026 (EPS est $1.39, revenue est $9.55B)
MDT ticked up on general market strength but remains the underperformer among the majors on a six-month basis. Evolut low-risk long-term data is favorable for the franchise, and the Netherlands TAV-in-TAV/SAV analysis showing SEV had lower TTE-invasive gradient discordance is a modest positive for the Evolut platform in the growing failed-bioprosthesis market. Intrepid TMVR is one of nine devices in the CHOICE-MI registry — durable MR reduction is real, but survival remains the bottleneck. Q1 earnings next week will set the near-term tone.
Abbott (ABT)
- Close $112.68, +2.09% on the day; 6-month return +1.79%; 52-week range $81.97-$137.49
- Market cap $196.3B; trailing P/E 35.66, forward P/E 18.58; beta 0.58
- Analyst target $119.40 (25 analysts, buy); range $103-$135
- Next earnings Oct 14, 2026 (EPS est $1.42, revenue est $12.99B)
ABT's MitraClip and TriClip franchises remain the volume leaders in transcatheter mitral and tricuspid repair, and the ESC 2025 Class I upgrade for TEER in ventricular SMR is a structural tailwind that has not fully repriced. The Cephea TMVR presence in the CHOICE-MI cohort is early-stage, but Abbott has the deepest structural heart pipeline in the group. Today's move reflects broad market strength more than valve-specific news.
Boston Scientific (BSX)
- Close $50.47, -1.87% on the day; 6-month return -33.35%; 52-week range $42.20-$109.50
- Market cap $73.1B; trailing P/E 20.86, forward P/E 14.68; beta 0.57
- Analyst target $62.69 (29 analysts, buy); range $44-$94
- Next earnings Oct 28, 2026 (EPS est $0.81, revenue est $5.26B)
BSX's 33% six-month drawdown reflects sector rotation and specific execution concerns rather than valve-franchise weakness per se. The Acurate neo2 platform continues to compete in TAVR, and the WATCHMAN LAA franchise adjacency to structural heart remains intact. Analyst target implies material upside, but the stock needs a positive earnings catalyst next quarter.
Anteris Technologies (AVR.AX)
- Close A$13.23, +1.38% on the day; 6-month return +65.37%; 52-week range A$5.20-$15.47
- Market cap A$1.3B; forward P/E -6.1 (pre-revenue)
- Analyst target A$13.00 (1 analyst, hold)
The DurAVR bio-mimetic single-piece valve continues to generate investor enthusiasm on the promise of superior hemodynamics and durability. Epic Cosmos's earlier-reintervention signal is precisely the market Anteris is positioning against — but the company remains pre-pivotal for its US IDE, and the +65% six-month move reflects narrative more than data.
Market outlook: The sector sits at an inflection where procedural volume growth (TAVR up >10-fold since 2016) meets the first credible long-term durability signals. The Epic Cosmos preprint is unlikely to move Edwards or Medtronic near-term but should raise the bar for future guideline updates on age thresholds. TEER and TTVR remain the growth stories — ESC 2025's Class I upgrade for ventricular SMR TEER and Class IIa for TTVR create structural tailwinds Abbott and Edwards are both positioned to capture.
Clinical Trial Updates
No new registrational trial data today. The TRINITY European cohort of LuX-Valve Plus and the CHOICE-MI TMVR registry are the closest today comes to trial-adjacent evidence, and both are single-arm observational.
Forward look: The Epic Cosmos preprint will likely draw a formal peer-reviewed submission within 60-90 days; expect both surgical and interventional societies to weigh in on how earlier TAVR valve failure squares with the ESC 2025 age-70 pivot before TCT 2026's late-breaker slate lands.